Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Positive results from the DESTINY-Breast09 phase III trial showed Enhertu (trastuzumab deruxtecan) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) ... For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination ...

ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) ... Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis.

On Jan. 27, the Food and Drug Administration (FDA) granted approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for patients with unresectable or metastatic HR-positive, HER2-low or -ultralow breast ...

With ENHERTU (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and ...